SGLT2 inhibitors in cardiovascular medicine.
作者信息
Varzideh Fahimeh, Kansakar Urna, Santulli Gaetano
机构信息
Department of Medicine, Einstein-Mount Sinai Diabetes Research Center (ES-DRC), Fleischer Institute for Diabetes and Metabolism (FIDAM), Albert Einstein College of Medicine, 1300 Morris Park Avenue, New York, NY 10461, USA.
Department of Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Einstein Institute for Aging Research, Albert Einstein College of Medicine, 1300 Morris Park Avenue, New York, NY 10461, USA.
出版信息
Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):e67-e68. doi: 10.1093/ehjcvp/pvab039.
Abstract
摘要
相似文献
1
SGLT2 inhibitors in cardiovascular medicine.心血管医学中的钠-葡萄糖协同转运蛋白2（SGLT2）抑制剂
Eur Heart J Cardiovasc Pharmacother. 2021 Jul 23;7(4):e67-e68. doi: 10.1093/ehjcvp/pvab039.
2
How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.SGLT2（钠-葡萄糖共转运蛋白 2）抑制剂和 GLP-1（胰高血糖素样肽-1）受体激动剂如何降低心血管结局？：已完成和正在进行的机制试验。
Arterioscler Thromb Vasc Biol. 2020 Mar;40(3):506-522. doi: 10.1161/ATVBAHA.119.311904. Epub 2020 Jan 30.
3
How should we monitor the cardiovascular benefit of sodium-glucose cotransporter 2 inhibition?我们应如何监测钠-葡萄糖协同转运蛋白2抑制剂的心血管获益？
Cardiovasc Diabetol. 2020 Dec 7;19(1):206. doi: 10.1186/s12933-020-01191-5.
4
Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂对非糖尿病患者心血管和代谢结局的影响：一项随机对照试验的系统评价和荟萃分析。
J Am Heart Assoc. 2021 Feb;10(5):e019463. doi: 10.1161/JAHA.120.019463. Epub 2021 Feb 24.
5
Renal and Cardiac Implications of Sodium Glucose Cotransporter 2 (SGLT2) Inhibitors: The State of the Science.钠-葡萄糖共转运蛋白 2（SGLT2）抑制剂的肾脏和心脏影响：科学现状。
Ann Pharmacother. 2018 Dec;52(12):1238-1249. doi: 10.1177/1060028018783661. Epub 2018 Jun 17.
6
Favorable pleiotropic effects of sodium glucose cotransporter 2 inhibitors: head-to-head comparisons with dipeptidyl peptidase-4 inhibitors in type 2 diabetes patients.钠-葡萄糖共转运蛋白 2 抑制剂的有利的多效性作用：与 2 型糖尿病患者的二肽基肽酶-4 抑制剂的头对头比较。
Cardiovasc Diabetol. 2020 Feb 12;19(1):17. doi: 10.1186/s12933-020-0990-2.
7
A new class of drugs for heart failure: SGLT2 inhibitors reduce sympathetic overactivity.一类用于治疗心力衰竭的新型药物：钠-葡萄糖协同转运蛋白2抑制剂可降低交感神经过度活动。
J Cardiol. 2018 May;71(5):471-476. doi: 10.1016/j.jjcc.2017.12.004. Epub 2018 Feb 4.
8
SGLT2 inhibitors for primary prevention of cardiovascular events.用于心血管事件一级预防的钠-葡萄糖协同转运蛋白2抑制剂
J Diabetes. 2020 Jan;12(1):5-7. doi: 10.1111/1753-0407.13004. Epub 2019 Nov 21.
9
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.钠-葡萄糖协同转运蛋白 2 抑制剂与心血管结局：系统评价和荟萃分析。
Eur J Prev Cardiol. 2018 Mar;25(5):495-502. doi: 10.1177/2047487318755531. Epub 2018 Jan 26.
10
Efficacy and renal outcomes of SGLT2 inhibitors in patients with type 2 diabetes and chronic kidney disease.SGLT2 抑制剂在 2 型糖尿病合并慢性肾脏病患者中的疗效和肾脏结局。
Postgrad Med. 2019 Jan;131(1):31-42. doi: 10.1080/00325481.2019.1549459. Epub 2018 Nov 30.
引用本文的文献
1
Metabolic Disturbances Involved in Cardiovascular Diseases: The Role of Mitochondrial Dysfunction, Altered Bioenergetics and Oxidative Stress.心血管疾病中的代谢紊乱：线粒体功能障碍、生物能量改变及氧化应激的作用
Int J Mol Sci. 2025 Jul 15;26(14):6791. doi: 10.3390/ijms26146791.
2
Effects of SGLT2 Inhibitor in Patients with Diabetes with Newly Diagnosed Acute Myocardial Infarction: A Multicenter Prospective Cohort Study.钠-葡萄糖协同转运蛋白2抑制剂对新诊断急性心肌梗死糖尿病患者的影响：一项多中心前瞻性队列研究
Cardiovasc Drugs Ther. 2025 May 22. doi: 10.1007/s10557-025-07716-y.
3
Influence of sodium-glucose cotransporter 2 inhibitors on the triglyceride-glucose index in acute myocardial infarction patients with type 2 diabetes mellitus.钠-葡萄糖协同转运蛋白2抑制剂对2型糖尿病急性心肌梗死患者甘油三酯-葡萄糖指数的影响
Cardiovasc Diagn Ther. 2024 Dec 31;14(6):1096-1107. doi: 10.21037/cdt-24-287. Epub 2024 Dec 11.
4
Exogenous Ketones in Cardiovascular Disease and Diabetes: From Bench to Bedside.心血管疾病和糖尿病中的外源性酮体：从实验台到病床边
J Clin Med. 2024 Dec 4;13(23):7391. doi: 10.3390/jcm13237391.
5
GLP-1 receptor agonists and SGLT2 inhibitors: new anti-aging tools?胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂：新型抗衰老工具？
Future Cardiol. 2025 Jan;21(1):5-8. doi: 10.1080/14796678.2024.2433381. Epub 2024 Nov 26.
6
Sodium-glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes.恩格列净通过抑制钠-葡萄糖共转运蛋白 2 改善 2 型糖尿病患者的认知功能障碍。
J Diabetes Investig. 2024 Nov;15(11):1596-1603. doi: 10.1111/jdi.14306. Epub 2024 Sep 10.
7
Editorial: Frailty and oxidative stress.社论：衰弱与氧化应激
Front Aging. 2024 Mar 6;4:1345486. doi: 10.3389/fragi.2023.1345486. eCollection 2023.
8
The Ketogenic Effect of SGLT-2 Inhibitors-Beneficial or Harmful?SGLT-2抑制剂的生酮作用——有益还是有害？
J Cardiovasc Dev Dis. 2023 Nov 16;10(11):465. doi: 10.3390/jcdd10110465.
9
Transient receptor potential vanilloid type 1: cardioprotective effects in diabetic models.瞬时受体电位香草酸亚型 1：在糖尿病模型中的心脏保护作用。
Channels (Austin). 2023 Dec;17(1):2281743. doi: 10.1080/19336950.2023.2281743. Epub 2023 Nov 20.
10
Ketone Bodies Rescue Mitochondrial Dysfunction Via Epigenetic Remodeling.酮体通过表观遗传重塑挽救线粒体功能障碍。
JACC Basic Transl Sci. 2023 Jul 5;8(9):1123-1137. doi: 10.1016/j.jacbts.2023.03.014. eCollection 2023 Sep.
本文引用的文献
1
Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes.降低2型糖尿病心血管风险的降糖药物
N Engl J Med. 2021 Apr 1;384(13):1248-1260. doi: 10.1056/NEJMcp2000280.
2
Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.索格列净治疗伴有近期恶化心力衰竭的糖尿病患者。
N Engl J Med. 2021 Jan 14;384(2):117-128. doi: 10.1056/NEJMoa2030183. Epub 2020 Nov 16.
3
Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.恩格列净治疗心力衰竭的心血管和肾脏结局。
N Engl J Med. 2020 Oct 8;383(15):1413-1424. doi: 10.1056/NEJMoa2022190. Epub 2020 Aug 28.
4
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.达格列净治疗射血分数降低的心力衰竭患者。
N Engl J Med. 2019 Nov 21;381(21):1995-2008. doi: 10.1056/NEJMoa1911303. Epub 2019 Sep 19.
5
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.卡格列净与2型糖尿病患者的心血管及肾脏事件
N Engl J Med. 2017 Nov 23;377(21):2099. doi: 10.1056/NEJMc1712572.
Zotero 插件